binimetinib

The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved by the agency previously, either as a single ingredient drug, or as part of a...

Following Array Biopharma Inc (NASDAQ: ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink thinks it will require a sizeable commercial effort to capture share in a market that has plateaued...

Shares of Array Biopharma Inc (NASDAQ: ARRY), a biopharmaceutical company that focuses on drugs to treat patients suffering from cancer, lost more than 12 percent early Monday morning after announcing a disappointing update to one of its therapies. Array Biopharma announced in a press release that...

Shares of Array Biopharma Inc (NASDAQ: ARRY) continue its bull run Tuesday, climbing more than 6 percent after surging 81 percent Monday on the heels of its positive late-stage skin cancer trial results. The study evaluating encorafenib and binimetinib in patients with "untreaded or 1L...